The present invention relates to the use of secretagogue peptides, which, administered in a pharmaceutical composition in repeated fashion, prevent and eliminate deposits of pathological fibrotic material in internal parenchymal tissue, such as the liver, lungs, oesophagus, small intestine, kidneys, blood vessels and joints, and also systemic forms of cutaneous fibrosis of any aetiopathogeny. Additionally, these peptides impede and eliminate the deposit of amyloid and hyaline material in any chemical form or tissue manifestation, including in respect of the brain, cerebellum, blood vessels, liver, intestines, kidneys, spleen, pancreas, joints and the skin. In this way, dysfunction in cells, tissue and organs affected by such abnormal deposits is corrected. Administered by infiltration or topically, the peptides of the present invention contribute to preventing and eliminating keloids and hypotrophic scars on the skin as a consequence of burns and other cutaneous traumas.
